Celator Pharmaceuticals Inc (NASDAQ:CPXX) announced that a Phase 2 pharmacokinetic and pharmacodynamics (PK/PD) study evaluating the effects of VYXEOS™ (CPX-351) on cardiac depolarization/repolarization has …
Seadrill Ltd (NYSE:SDRL) fell 5.28% to $6.
Celator Pharmaceuticals Inc (NASDAQ:CPXX) announced that the independent Data and Safety Monitoring Board (DSMB) for the Company’s Phase 3 clinical study of CPX-351 (cytarabine:daunorubicin) …
Celator Pharmaceuticals Inc (NASDAQ:CPXX), a biopharmaceutical company that is transforming the science of combination therapy and developing products to improve patient outcomes in cancer, …
In a research report published Friday, Roth Capital analyst Joseph Pantginis reiterated a Buy rating on Celator Pharmaceuticals Inc (NASDAQ:CPXX) with a price target …
H.C.
Shares of Celator Pharmaceuticals Inc (NASDAQ:CPXX) closed yesterday up almost 24% after the company reported that CPX-351, a drug aimed to treat Acute Myeloid Leukemia …
Himax Technologies, Inc. (ADR) (NASDAQ:HIMX) shares increased 4.
